睿知中国疾病研究地图
候选清单0

正在招募原发性胆汁性胆管炎III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

ClinicalTrials.gov 上登记的一项原发性胆汁性胆管炎开放试验。牵头方不是本站收录的医院;本站收录的 35 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 35

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心广东医科大学附属医院Affiliated Hospital of Guangdong Medical University湛江医院页面
  2. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  3. 研究中心宝鸡市人民医院Baoji People's HospitalBaoji医院页面
  4. 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
  5. 研究中心首都医科大学附属北京佑安医院Beijing Youan Hospital, Capital Medical University北京医院页面
  6. 研究中心中日友好医院China-Japan Friendship Hospital北京医院页面
  7. 研究中心重庆大学附属三峡医院Chongqing University Three Gorges Hospital重庆医院页面
  8. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
  9. 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
  10. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  11. 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
  12. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  13. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  14. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  15. 研究中心哈尔滨医科大学第四附属医院Fourth Hospital Of Harbin Medical University哈尔滨医院页面
  16. 研究中心杭州市西溪医院Hangzhou Xixi Hospital杭州医院页面
  17. 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
  18. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  19. 研究中心临沂市人民医院Linyi People's Hospital临沂医院页面
  20. 研究中心福建医科大学孟超肝胆医院Mengchao Hepatobiliary Hospital of Fujian Medical University福州医院页面
  21. 研究中心北京大学深圳医院Peking University Shenzhen Hospital深圳医院页面
  22. 研究中心上海交通大学医学院附属仁济医院Renji Hospital上海医院页面
  23. 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
  24. 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
  25. 研究中心重庆医科大学附属第二医院Second Affiliated Hospital of Chongqing Medical University重庆医院页面
  26. 研究中心深圳市第三人民医院Shenzhen Third People's Hospital深圳医院页面
  27. 研究中心十堰市太和医院Taihe Hospital十堰医院页面
  28. 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
  29. 研究中心天津市第一中心医院Tianjin First Central Hospital天津医院页面
  30. 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
  31. 研究中心天津市第三中心医院Tianjin Third Central Hospital天津医院页面
  32. 研究中心四川大学华西医院West China Hospital成都医院页面
  33. 研究中心厦门市中医院Xiamen Hospital厦门医院页面
  34. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  35. 研究中心上海交通大学医学院附属新华医院Xinhua Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07282353,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Documented liver biopsy results consistent with PBC;

    入选标准第 6 条

  3. 3 months prior to randomization: obeticholic acid (OCA), azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, systemic corticosteroids and budesonide (˃2 weeks); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin).

    排除标准第 26 条

    12 months prior to randomization: antibodies or immunotherapy directed against ILs or other cytokines or chemokines;

    排除标准第 28 条

    Poor blood pressure control is indicated after treatment by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening;

    排除标准第 34 条

  4. History of ALP above 1.0× ULN for at least 6 months

    入选标准第 4 条

    ALP ≥1.67× ULN

    入选标准第 9 条

    ALT≤5× ULN

    入选标准第 10 条

    AST ≤5× ULN

    入选标准第 11 条

    TB <2× ULN

    入选标准第 12 条

    Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2 (calculated by CKD-EPI equation)

    入选标准第 13 条

    Platelet count ≥ 1.0× LLN (No thrombocytopenia-related treatment within the past two weeks)

    入选标准第 14 条

    White blood cells count (WBC) >3×109/L

    入选标准第 16 条

    Absolute neutrophil count (ANC) >1.5×109/L

    入选标准第 17 条

    Hemoglobin A1c (HbA1c) ≤9.0%;

    入选标准第 18 条

    INR ≤ 1.0× ULN. For participants on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease;

    入选标准第 19 条

    Advanced PBC as defined by the Rotterdam criteria (albumin<1.0×LLN AND TB >1.0× ULN);

    排除标准第 3 条

  5. Autoimmune hepatitis (AIH) (simplified AIH diagnostic score >6), PBC-AIH overlap syndrome, or overlap with other autoimmune liver diseases

    排除标准第 13 条

    Positive HBsAg or positive HCV RNA (tested for in case of known cured HCV infection or positive HCV Ab at screening)

    排除标准第 14 条

  6. Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.

    入选标准第 20 条

    Pregnancy, planned pregnancy, lactation;

    排除标准第 35 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07282353,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Must have given written informed consent (signed and dated) and any authorizations required by local law;
  2. When signing ICF age ≥18 years ≤75 years, male or female;
  3. Meets the diagnostic criteria of PBC, based on any two of the following criteria:
  4. History of ALP above 1.0× ULN for at least 6 months
  5. Positive antimitochondrial antibody (AMA) titer (>1:40 on immunofluorescence or M2 positive by ELISA) or positive PBC- specific antinuclear antibody (ANA) (either SP100 or GP210 positive)
  6. Documented liver biopsy results consistent with PBC;
  7. UDCA≥6 months before randomization and a stable dose ≥3 months after the efficacy was poor [meeting inclusion criteria (5)a], or UDCA was not tolerated, and stop taking UDCA (no UDCA use for ≥3 months before randomization);
  8. Laboratory parameters measured at screening period meet the following criteria:
  9. ALP ≥1.67× ULN
  10. ALT≤5× ULN
  11. AST ≤5× ULN
  12. TB <2× ULN
  13. Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2 (calculated by CKD-EPI equation)
  14. Platelet count ≥ 1.0× LLN (No thrombocytopenia-related treatment within the past two weeks)
  15. Albumin> 35g/L
  16. White blood cells count (WBC) >3×109/L
  17. Absolute neutrophil count (ANC) >1.5×109/L
  18. Hemoglobin A1c (HbA1c) ≤9.0%;
  19. INR ≤ 1.0× ULN. For participants on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease;
  20. Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.

排除标准:Exclusion Criteria:

  1. Previous exposure to CS0159;
  2. History of allergy to the CS0159 or its excipients or drugs of similar chemical classes;
  3. Advanced PBC as defined by the Rotterdam criteria (albumin<1.0×LLN AND TB >1.0× ULN);
  4. Patients who have had clinically significant complications of hepatic cirrhosis with clinically significant portal hypertension (CSPH), including the following:
  5. History of liver transplantation, current placement on a liver transplant list, current MELD -Na score ≥ 12;
  6. History of confirmed esophagogastric variceal bleeding;
  7. Clinically significant ascites requiring intervention, such as sodium restriction, diuretic therapy, or therapeutic paracentesis;
  8. Any secondary complications resulting from clinically significant ascites, such as spontaneous bacterial peritonitis, hepatorenal syndrome, or hepatic hydrothorax;
  9. Hepatic encephalopathy requiring drug therapy;
  10. Portopulmonary hypertension and/or hepatopulmonary syndrome;
  11. Hepatocellular carcinoma;
  12. Other concomitant liver disease including:
  13. Autoimmune hepatitis (AIH) (simplified AIH diagnostic score >6), PBC-AIH overlap syndrome, or overlap with other autoimmune liver diseases
  14. Positive HBsAg or positive HCV RNA (tested for in case of known cured HCV infection or positive HCV Ab at screening)
  15. Primary sclerosing cholangitis (PSC)
  16. History or clinical evidence of Alcoholic liver disease (ALD)
  17. Biopsy confirmed Non-alcoholic steatohepatitis (NASH)
  18. Gilbert's Syndrome
  19. History or evidence of alpha-1 antitrypsin deficiency
  20. Liver stiffness measured by transient elastography (TE) > 16.9 Kpa;
  21. Patient has a positive test for HIV at screening, or active syphilis [defined as positive Treponema pallidum antibody (TP Ab) and a rapid plasma reagin (RPR) card test titer ≥1:8; for low titers (e.g., 1:1 or 1:2), clinical judgment is required to determine if it is active syphilis];
  22. Administration of the following medications are prohibited as specified below:
  23. Use of medications, food, and drinks (e.g., grapefruit juice) that are strong or moderate CYP3A4 inhibitors or inducers within 14 days before randomization;
  24. Use of P-glycoprotein (P-gp) substrate drugs within 14 days before randomization;
  25. 2 months prior to randomization: fibrates, glitazones, seladelpar and elafibranor.
  26. 3 months prior to randomization: obeticholic acid (OCA), azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, systemic corticosteroids and budesonide (˃2 weeks); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin).
  27. Patients with systemic treatment for pruritus (e.g., with bile acid sequestrants [BAS]) within 3 months prior to randomization.
  28. 12 months prior to randomization: antibodies or immunotherapy directed against ILs or other cytokines or chemokines;
  29. Medical conditions that may cause non-hepatic increases in ALP (e.g., paget's disease);
  30. Patients with severe arrhythmia, or a QTcF interval corrected by Fridericia's formula ≥450 ms (males) or ≥470 ms (females) at screening [Fridericia's formula: QTcF=QT/(RR\^0.33)];
  31. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease, prior or planned (during the study period) bariatric surgery (such as gastroplasty, roux-en-Y gastric bypass);
  32. History of malignancy (except for those with a disease-free survival of ≥5 years) or currently under evaluation for malignancy. Except for cases with long-term stable disease and assessed by the investigator as having no significant impact on the trial-such as cured squamous or non-invasive basal cell skin carcinoma, cervical carcinoma in situ, mild to moderate cervical dysplasia, or incidental prostate cancer stage T1a.
  33. Drug abuse or heavy alcohol use from 12 months prior to randomization throughout the entire clinical study period. Heavy alcohol use is defined as an average weekly alcohol consumption of more than approximately 7 standard drinks for females and more than approximately 14 standard drinks for males. One standard drink is defined as any beverage containing 14g of pure alcohol, such as 12 oz/360 mL of beer (5% alcohol), 8 oz/240 mL of malt liquor (7% alcohol), 5 oz/150 mL of wine (12% alcohol), or 1.5 oz/45 mL of distilled spirits (40% alcohol);
  34. Poor blood pressure control is indicated after treatment by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening;
  35. Pregnancy, planned pregnancy, lactation;
  36. Treatment with any other investigational therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening;
  37. Mental instability or incompetence that may compromise the validity of informed consent or ability to adhere to study requirements;
  38. Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study, as judged by the investigator.

引自 ClinicalTrials.gov, NCT07282353, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07282353,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07282353